2017 BIOPHARMA COLD CHAIN SOURCEBOOK OVERVIEW
This is the eighth edition of the Biopharma Cold Chain Sourcebook. Since its inception, it has been developed to serve two purposes:
Our intent is to help manufacturers, regulators and suppliers of specialized products and services to understand the scale and direction of the cold-chain biopharma business, and to have some better basis for planning and managing their role in it. In this year’s update, we have looked more deeply at some of the market drivers, such as clinical trials, active pharmaceutical ingredients (APIs), and controlled room-temperature shipping services.
An important note about “cold chain:” while this term has been in common use in the logistics industry (and for other types of shipments, such as food products or certain chemicals), industry experts are gradually changing the focus to “temperature-controlled” or “temperature sensitive” shipping. While a relatively small number of products require refrigerated (2-8°C) or various levels of “frozen” (-20°C or lower), a much greater number of products have labels specifying “controlled room temperature” (15-30°C), commonly referred to as CRT. Historically, CRT products have been shipped via standard trucking or air modes, with perhaps some care taken to avoid obviously out-of-standard conditions (such as in open air during winter). Increasingly, CRT will mean a monitored, regulated logistics process. We address aspects of this in the Sourcebook, but the detailed economic analysis is primarily focused on refrigerated products.
We consider along with drugs the transport of commercial blood products, vaccines and other biologics that need to be kept cold. Blood banks, which collect blood from communities and then give most of it back in a non-commercial way, are out of scope. Likewise cord-blood banks and tissue and organs in general, though we do make note of new stem-cell products which are starting to appear from this source.
Logistics for clinical trials, which generate tens of billions of dollars of economic activity worldwide – we consider separately, not as part of the everyday commercial flow of cold-chain pharma products which is our main focus.
Biotechnology products, blood products and vaccines are derived from living cells and, like living cells, are susceptible to injury from excessive heat and often also to injury from freezing, with the accompanying loss of their therapeutic and financial value. Since the 1980s, when the commercial biotechnology industry introduced its first products, the global market now measures more than $150 billion in value, and the special logistics for maintaining the quality of temperature-sensitive products as they are shipped around the world account for more than 11% of all biopharma logistics spending.
In analyzing the biopharma cold chain market, there are three necessary steps, each of which has been pioneered by the Sourcebook analytics:
What portion of the global pharma and biotech market requires cold-chain storage and transportation?
What transportation modes are employed, depending on whether a shipment is local, national or transnational?
What the general trends in pricing for packaging materials for cold chain shipments, and for logistics services, and then how do these change specifically for life sciences products?
These questions address the mechanics of making meaningful economic summaries and projections of the biopharma cold chain market. A comparable level of detailed analysis is necessary for operational issues: what regulatory requirements need to be met (across more than 25 separate national health-authority regulatory frameworks, as well as technical requirements from such organizations as US Pharmacopeia, the International Air Transport Assn. and the International Standards Organisation). Finally, the analysis takes into consideration the technological trends in the industry: the use of active (powered) shipping containers, or the ability to do real-time tracking of location and physical conditions of shipments as they are being transported, to name two.
Like other types of services to the global biopharma industry, logistics and supply chain management are undergoing significant changes. More specialty pharmaceuticals (the high-growth area of the industry, and one where cold-chain transport is very common) is gravitating toward a direct-distribution model, with individualized dosages being sent to patients or specialty clinics. The biopharma industry is handing off more and more of the shipping and distribution process to third-party logistics providers (3PLs), even as regulatory burdens become heavier. Electronic tracking of shipments, including near real-time reporting of location and condition, is becoming a desired option. “Good Distribution Practices” (GDPs) are more and more looking like an extension of Good Manufacturing Practices (GMPs)—the standard of performance in the regulated biopharma industry. The 2017 Sourcebook has updated information on biopharma product introductions and commercial activity, updates and projections on regulatory requirements worldwide, more detailed analysis of transportation costs, and closer analysis of clinical logistics trends. Technology developments in packaging materials, instrumentation and data services are reviewed. Finally there is a comprehensive directory of service providers and carriers, excerpts of relevant government regulations, and data sources in appendices.